Sources

8 Total Sources

Lilly's Retatrutide Cuts Weight by 22.6% in 2 Phase 3 Obesity Trials

Investors | Eli Lilly and Company22h ago

Eli Lilly's Retatrutide Achieves Significant Weight and A1C Reductions in Two Phase 3 Obesity Trials

StockTitan22h ago

Eli Lilly Retatrutide Phase 3: Up to 22.6% Weight Loss | LLY Stock News

Stocktwits10h ago

Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing

MD Magazine22h ago

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials | HCPLive

GuruFocus.com22h ago

Eli Lilly (LLY) Reports Positive Phase 3 Trial Results for Retat

Instagram22h ago

Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio.

excelmale.com22h ago

Retatrutide (GLP-3): Real Dosing, Results & Side Effects

doctormedica.co22h ago

What Is Retatrutide? Triple Agonist GIP/GLP-1/Glucagon Peptide Overview